Ilmarinen Mutual Pension Insurance Co increased its holdings in shares of Danaher Corporation (NYSE:DHR – Free Report) by 9.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,700 shares of the conglomerate’s stock after acquiring an additional 9,200 shares during the period. Ilmarinen Mutual Pension Insurance Co’s holdings in Danaher were worth $24,082,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. E Fund Management Hong Kong Co. Ltd. boosted its holdings in Danaher by 24.6% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 2,658 shares of the conglomerate’s stock worth $589,000 after acquiring an additional 524 shares in the last quarter. Sumitomo Life Insurance Co. grew its stake in shares of Danaher by 1.2% in the third quarter. Sumitomo Life Insurance Co. now owns 6,670 shares of the conglomerate’s stock worth $1,478,000 after acquiring an additional 80 shares during the last quarter. Whittier Trust Co. grew its stake in shares of Danaher by 0.8% in the third quarter. Whittier Trust Co. now owns 398,812 shares of the conglomerate’s stock worth $87,663,000 after acquiring an additional 3,327 shares during the last quarter. TIAA Trust National Association increased its holdings in shares of Danaher by 81.0% during the third quarter. TIAA Trust National Association now owns 391 shares of the conglomerate’s stock valued at $87,000 after acquiring an additional 175 shares in the last quarter. Finally, Advisors Asset Management Inc. bought a new position in shares of Danaher during the third quarter valued at $1,348,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Danaher Stock Down 3.1%
DHR stock opened at $220.42 on Friday. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The business has a fifty day moving average price of $224.82 and a 200-day moving average price of $201.66. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.63 and a quick ratio of 1.29. The stock has a market capitalization of $155.07 billion, a P/E ratio of 36.08, a P/E/G ratio of 2.89 and a beta of 0.76.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating the consensus estimate of $1.92 by $0.19. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The company had revenue of $6.55 billion for the quarter, compared to analysts’ expectations of $6.56 billion. During the same period last year, the firm posted $1.89 earnings per share. Danaher’s revenue was up 8.3% compared to the same quarter last year. Equities analysts forecast that Danaher Corporation will post 8.59 earnings per share for the current fiscal year.
Danaher Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 26.19%.
Insider Transactions at Danaher
In other news, CAO Christopher Bouda sold 7,598 shares of the firm’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $234.56, for a total transaction of $1,782,186.88. Following the sale, the chief accounting officer owned 9,107 shares of the company’s stock, valued at $2,136,137.92. This trade represents a 45.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gregory Milosevich sold 2,100 shares of Danaher stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $230.62, for a total transaction of $484,302.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $5,158,277.54. This represents a 8.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 10.80% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on DHR. Robert W. Baird upped their price target on shares of Danaher from $246.00 to $254.00 and gave the stock an “outperform” rating in a research note on Thursday, October 22nd. Guggenheim increased their price objective on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. TD Cowen raised their price objective on shares of Danaher from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Finally, Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Monday, October 26th. Eighteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $242.91.
Get Our Latest Stock Analysis on DHR
Danaher Company Profile
Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.
Featured Stories
- Five stocks we like better than Danaher
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
